NDL-2

N/A

Report date: 2025/10/11 10:06:13
NMEFirst In Class

Base Information

Drug NameNDL-2
Drug Alias NameNDL2NDL-2
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionProgrammed death-ligand 1 degraders
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesQimr Berghofer Medical Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesQimr Berghofer Medical Research InstituteKazia Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A